Skip to main content
Clinical Trials/EUCTR2011-005806-32-DE
EUCTR2011-005806-32-DE
Active, not recruiting
Not Applicable

Clinical Study to Collect Clinical Data Sets for Development of Insulin Glargine Titration Algorithms - Delta Study

ikfe GmbH0 sitesJanuary 3, 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 diabetes mellitus receiving BOT Therapy or insulin therapy only
Sponsor
ikfe GmbH
Status
Active, not recruiting
Last Updated
13 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 3, 2012
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
ikfe GmbH

Eligibility Criteria

Inclusion Criteria

  • 1\.Type 2 diabetes mellitus
  • 2\.Improvement of an existing BOT with Insulin Glargine \+ OAD or Insulin Glargine alone
  • 3\.HbA1c between 6\.5% and 9\.5% inclusively
  • 4\.Age between 30 and 75 years inclusively
  • 5\.Body mass index \=40 kg/m2
  • 6\.Patient consents that his/her family physician will be informed of trial participation
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 50

Exclusion Criteria

  • 1\.Type 1 diabetes mellitus
  • 2\.Instable OAD therapy during the last 6 weeks prior to the study
  • 3\.Severe retinopathy, hepatic or renal dysfunction or clinically relevant other major diseases
  • 4\.Lack of compliance or other justifications that, in the discretion of the investigator, precludes satisfactory participation in the study
  • 5\.Subject without legal capacity
  • 6\.Pregnant or lactating women
  • 7\.History of drug or alcohol abuse within the last five years prior to screening
  • 8\.Anamnestic history of hypersensitivity to the study drugs (or any component of the study drug) or to drugs with similar chemical structures
  • 9\.History of severe or multiple allergies
  • 10\.Treatment with any other investigational drug within 3 months prior to screening

Outcomes

Primary Outcomes

Not specified

Similar Trials